MiNK Therapeutics, Inc.
INKT · Nasdaq · United States
Share price · INKT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INKT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Oct 2026+6.5%
Nothing announced by INKT that day or the session before.
- 21 Oct 2026+7.7%
Nothing announced by INKT that day or the session before.
- 7 Jul 2026-8.1%
Nothing announced by INKT that day or the session before.
- 28 May 2026+19.8%
- 14 Apr 2026+16.9%
Nothing announced by INKT that day or the session before.
- 27 Mar 2026+14.4%
- 11 Mar 2026-17.2%
- 10 Mar 2026+29.3%
- 6 Mar 2026-6.1%
Nothing announced by INKT that day or the session before.
- 5 Jan 2026+8.5%
- Day beforeDirector or principal officer change
Share of unusual movement by asset
For each asset, the share of INKT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Invariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigenCell therapy | Multiple MyelomaGastric Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.2M | $1.8M | $7.5M | $2.5M-$1.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.9M | $8.8M | $3.1M-$2.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $1.2M | $9.5M | $2.7M-$1.7M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.1M | $14M | $2.9M-$0.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.8M | $1.7M | $4.2M-$1.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.3M | $3.2M | $2.8M-$1.3M operating cash flow | report ↗ |
| 2024-Q3 | — | $0.5M | $6.3M | $1.8M-$3.0M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.8M | $9.3M | $2.7M-$2.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.5M | $5.8M | $3.8M-$2.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.4M | $6.4M | $5.1M-$4.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.6M | $11M | $6.2M-$4.2M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.2M | $15M | $5.7M-$4.4M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.2M | $24M | $6.3M-$5.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.9M | $30M | $6.1M-$4.6M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.3M | $35M | $7.8M-$4.2M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.3M | $0.8M | $14M-$3.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $5.8M | $13M | $3.1M-$5.9M operating cash flow | report ↗ |
MiNK Therapeutics did not disclose revenue for 2025. R&D expense was $5.76M, down 9.1% YoY, and the company ended the year with cash and equivalents of $13.36M. Full-year net loss was $12.5M, or $2.93 per share, versus $10.8M in 2024, while the Q4 net loss was $2.6M, or $0.56 per share. The company noted it raised an additional $3.0M through its at-the-market program after year end, providing a runway through 2026.
Management expects to initiate the Phase 2 ARDS/hypoxemic pneumonia trial in 1H 2026, with early data by year-end, and anticipates first dosing in the GVHD Phase 1 trial in May 2026 with preliminary data in 2H 2026. Non-dilutive support includes the C-Further Consortium collaboration, an NIH NIAID STTR grant, and the Mary Gooze philanthropic award. Presentations at Keystone Symposia and SITC 2025 highlighted iNKT cell depletion in end-stage IPF and durable responses in checkpoint-resistant tumors. Leadership additions included Terese Hammond, John Holcomb, and Melissa Orilall.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($120K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer · director, Chief Executive Officer | Open-market sale | 6,938 | $10.56 | $73K | Form 4 |
| 2026-10-11 | Buell Jennifer · director, Chief Executive Officer | Option exercise | 23,191 | — | — | Form 4 |
| 2026-10-11 | Buell Jennifer · director, Chief Executive Officer | Option exercise (derivative) | 23,191 | — | — | Form 4 |
| 2026-09-01 | Corvese Brian · director | Award / grant | 1,633 | $10.95 | $18K | Form 4 |
| 2026-09-01 | Ryan Barbara · director | Award / grant | 1,622 | $10.95 | $18K | Form 4 |
| 2026-09-01 | Behner Peter · director | Award / grant | 1,485 | $10.95 | $16K | Form 4 |
| 2026-09-01 | Holcomb John Bradley · director | Award / grant | 1,233 | $10.95 | $14K | Form 4 |
| 2026-09-01 | WIINBERG ULF · director | Award / grant | 1,279 | $10.95 | $14K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 22 reporting institutions held 0.1M shares ($1.3M, 2.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 59,364 | $625K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 17,345 | $183K |
| 3 | Longbow Finance SA | 16,667 | $176K |
| 4 | UBS Group AG | 15,202 | $160K |
| 5 | VANGUARD FIDUCIARY TRUST CO | 8,287 | $87K |
| 6 | BlackRock, Inc. | 6,203 | $65K |
| 7 | Steward Partners Investment Advisory, LLC | 2,000 | $21K |
| 8 | Annis Gardner Whiting Capital Advisors, LLC | 200 | $2K |
| 9 | Tower Research Capital LLC (TRC) | 156 | $2K |
| 10 | MORGAN STANLEY | 104 | $1K |
| 11 | CITIGROUP INC | 91 | $958 |
| 12 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 18 | $190 |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 16 | $168 |
| 14 | Game Plan Financial Advisors, LLC | 16 | $168 |
| 15 | Clearstead Advisors, LLC | 14 | $148 |